Plasma Concentration vs Time
AI Analysis
Drug B shows a delayed Tmax (8h vs 4h for Drug A) suggesting slower absorption, potentially due to extended-release formulation. Drug A's higher initial peak may increase adverse effect risk. Monitor patients closely in first 4 hours.
Adverse Events by System
AI Image Analysis
🖼️
Drop an ECG, X-ray, or graph here
PNG · JPG · PDF accepted
Analysis Result
Findings: Graph shows a biphasic elimination curve consistent with a two-compartment pharmacokinetic model.
Key parameters: Distribution half-life ≈ 1.2h · Elimination half-life ≈ 8.4h · Apparent Vd ≈ 42 L/kg
Clinical implication: Extended dosing interval recommended. Consider TDM for narrow therapeutic index drugs.
Key parameters: Distribution half-life ≈ 1.2h · Elimination half-life ≈ 8.4h · Apparent Vd ≈ 42 L/kg
Clinical implication: Extended dosing interval recommended. Consider TDM for narrow therapeutic index drugs.